Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.